1. Which company produced the Kexing COVID-19 vaccine? Produced by Beijing Kexing Zhongwei Biotechnology Co., Ltd., a subsidiary of Kexing Holding Biotechnology Co., Ltd.+On February 7, 2020, Kexing Holding Biotechnology Co., Ltd. said that its subsidiary Beijing Kexing Zhongwei Biotechnology Co., Ltd. (hereinafter referred to as Kexing Zhongwei) has obtained more than 500 million US dollars for further research and development, capacity expansion and other development and business activities of novel coronavirus inactivated vaccine Clever. It is reported that Beijing Kexing Zhongwei Biotechnology Co., Ltd. was incorporated in Beijing Administration for Industry and Commerce on May 7, 2009. The company's business scope includes research and development of biological vaccine technology and diagnostic kit technology and technical services. On September 8, 2020, the regiment was awarded the honorary title of national advanced collective against COVID-19 by the Central Committee, the State Council and the Central Military Commission.
2. Kexing Holding Biotechnology Co., Ltd. Beijing Kexing Holding Biotechnology Co., Ltd. is a leading biopharmaceutical company in China. Kexing Holding Biotechnology is affiliated to Beijing Kexing Biological Products Co., Ltd., which is a biotechnology high-tech enterprise jointly funded by Beijing Kexing Biotechnology (Hong Kong) Co., Ltd. and Beijing Peking University Weiming Biological Engineering Group Co., Ltd. The company is registered in Peking University Biological City, Zhongguancun High-tech Park, Beijing, 200 1.
3. What is the actual protection rate of Kexing COVID-19 vaccine? According to Bloomberg, in clinical trials in Brazil, infected people can be divided into six categories: asymptomatic, very mild, mild, 1 moderate, 2 moderate and severe. The first two types of infected people do not need medical intervention.
The protection rate is 50.38%, and the following five symptoms are counted, that is, all infected people with symptoms. The number of subjects in the two groups is similar, 85 people in the vaccine group have symptoms, and the control group 167 people.
If only the infected people who need medical intervention are counted, that is, the last four situations, the protection rate of Kexing vaccine is the previously published data: 78%.
If there are only serious symptoms, the protection rate of Kexing vaccine is 100%.
Therefore, we can understand the function of Kexing vaccine in this way: Compared with the unvaccinated population, Kexing vaccine reduces the infection probability and symptoms by 50.38%. Although these vaccinators are still infected, the symptoms are very mild and do not need any medical intervention. Besides, no one who is vaccinated has a serious disease.